⏳ Fetching live dividend data...
Home › Calculator › ADXSD Dividend Calculator 2026
Advaxis, Inc. · OTC
Price: $3.85 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in ADXSD → $2284977444.72M in 10 years · $190,057,501,230,412.16/month
Advaxis, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing its proprietary Listeria monocytogenes (Lm) technology for antigen delivery products, primarily in the United States. Its pipeline includes ADXS-PSA, currently in Phase 2 clinical trials for metastatic prostate cancer; ADXS-503, undergoing Phase 1/2 clinical trials for non-small cell lung cancer; and ADXS-504, aimed at treating prostate cancer. The company is also advancing Lm Technology immunotherapies through clinical studies in broader disease areas, such as hotspot/off-the-shelf neoantigen-directed therapies, human papilloma virus-associated cancers, and prostate cancer. Advaxis has established collaborations and partnerships with various organizations, including Merck & Co., Inc., OS Therapies, LLC, Aratana Therapeutics Inc., Biocon Limited, Global BioPharma Inc., and Knight Therapeutics Inc. Founded in 2002, Advaxis, Inc. is headquartered in Monmouth Junction, New Jersey.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ADXSD position with:
Real after-tax yield depends on where you live and how you hold ADXSD.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 51.95% | 49.15% | $5,195 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 44.16% | 41.36% | $4,416 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 41.56% | 38.76% | $4,156 / yr |
| 🇬🇧 UK ISA | 0% | 51.95% | 49.15% | $5,195 / yr |
| 🇬🇧 UK Taxable | 8.75% | 47.40% | 44.60% | $4,740 / yr |
| 🇨🇦 TFSA | 0% | 51.95% | 49.15% | $5,195 / yr |
| 🇨🇦 CA Taxable | 25% | 38.96% | 36.16% | $3,896 / yr |
| 🇦🇺 Super (pension) | 15% | 44.16% | 41.36% | $4,416 / yr |
| 🇦🇺 AU Taxable | 30% | 36.37% | 33.57% | $3,637 / yr |
| 🇩🇪 DE Taxable | 26.375% | 38.25% | 35.45% | $3,825 / yr |
| 🇫🇷 FR Taxable | 30% | 36.37% | 33.57% | $3,637 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
ADXSD pays quarterly — 4 times per year. Next ex-div: TBD.
How ADXSD compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ADXSD sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2024-03-01 | 2,250,000 | $0.40 | $900.0K | ||
| M-Exempt | 2024-03-01 | 1,500,000 | $0.40 | $600.0K | ||
| M-Exempt | 2024-03-01 | 3,750,000 | $0.40 | $1.50M | ||
| M-Exempt | 2024-03-01 | 2,250,000 | $0.40 | $900.0K | ||
| M-Exempt | 2024-03-01 | 1,500,000 | $0.40 | $600.0K | ||
| M-Exempt | 2024-03-01 | 3,750,000 | $0.40 | $1.50M | ||
| M-Exempt | 2024-02-07 | 8,062,500 | $0.40 | $3.23M | ||
| F-InKind | 2024-02-07 | 2,586,905 | $1.25 | $3.22M | ||
| M-Exempt | 2024-02-07 | 8,437,500 | $0.40 | $3.38M | ||
| F-InKind | 2024-02-07 | 2,707,581 | $1.25 | $3.38M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ADXSD dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Advaxis, Inc. (ADXSD) is currently trading at $3.85, trading near its 52-week high. The current dividend yield is 51.95% based on an annual payout of $2.00 per share.
Advaxis, Inc. (ADXSD) is a healthcare stock currently trading at $3.85 with a dividend yield of 51.95%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →